We Welcome New investments!

AdminMed is seeking strategic partners and equity investors to accelerate the Company's growth.

Business Summary: AdminMed is revolutionizing the $100B GLP-1 weight-loss injection market. Our AdminPen™ eliminates the #1 reason 40% of patients quit Ozempic®/Mounjaro® within 12 months: painful weekly injections. With 30% of patients suffering severe needle phobia and injection site reactions affecting 15-20%, AdminPen transforms dreaded medical procedures into painless self-care. AdminPen has an annual global TAM of $12 billion.

Stage: The product is developed and is currently sold globally for research use.

Industry: Medical Devices, Drug-device combination products.

Unmet Clinical and Industry Need: The $100B Problem We Solve - 70 million Americans need GLP-1 drugs, but 40% quit within a year due to injection burden. Weekly injections cause anxiety, pain, and visible marks that stigmatize users. AdminPen makes these miracle drugs actually tolerable to take.

Solution: Our patented AdminPen device enables the more effective and painless delivery of any parenteral drugs, including weight-loss injectable drugs, cancer immunotherapies, dermatological actives, and hair growth treatments, uniformly into a 1 cm² skin area. The microneedle array is formed from a metal film and can be inexpensively manufactured using scalable, mature, high-volume, low-cost processes. The FDA classifies AdminPen as a Class II medical device with a 510(k) regulatory approval route. AdminPen can be used with any standard commercially available pen with a pre-filled drug cartridge or with any standard syringe.

Target Market: AdminPen microneedle device is an excellent fit for the painless delivery of existing and new parenteral drugs and vaccines. AdminMed will partner with pharmaceutical and vaccine manufacturers to enhance the effectiveness of their products. AdminPen can also be used by patients themselves for more effective and painless delivery of pharmaceutical drugs and injectable cosmetics that require frequent, at-home self-injection.

Customers: AdminMed will license and market its patented delivery platform to medical device and pharmaceutical companies to increase effectiveness and improve the delivery of their vaccines and medical drugs.

Business Model: AdminMed sells AdminPen, AdminPatch, and AdminStamp microneedle array products for research use to medical research institutions and medical device and pharmaceutical companies. Through our sales efforts, we have effectively marketed our product and generated promising pre-clinical data on its performance. We will license our technology and products to vaccine and drug manufacturers, charging a ~3-5% royalty on Net Drug Sales for an exclusive license in a specific therapeutic area. The licensing revenues will allow AdminMed to fund the development of large-scale manufacturing AdminPen devices and develop our own AdminPen-delivered products for strategic clinical indications and territories. Within 2-3 years of receiving funding, we will be well-positioned to be acquired by a large pharmaceutical or medical device company for approximately $250 million.

Competitors: Competing microneedle technologies are either very expensive and unreliable due to the use of exotic silicon microfabrication technologies (NanoPass) or require reformulation of the administered agent, resulting in long product development timelines and a costly regulatory approval pathway for drug-coated microneedles (Kindeva) and dissolvable microneedles (Corium). None of our competitors can produce the convex microneedle arrays required for the reliable insertion of all microneedles into flexible skin.

Competitive Advantage: We hold four US and EU Granted Patents covering our novel product design, method of use, and method of manufacturing. We own our proprietary robotic-based manufacturing process. AdminMed is the only company capable of producing convex hollow metal microneedle arrays required to safely and reliably insert all individual microneedles into flexible skin and deliver the already approved vaccines and drugs. The patented, painless AdminPen device is a unique and superior device that allows effective delivery of all vaccines, including particle-based and DNA vaccines, liquid drugs, or injectable cosmetics uniformly into a 1 cm2 area of the skin and can be inexpensively manufactured using mature high-volume, low-cost processes, and follows the 510(k) regulatory approval route.

Competitive Advantage of ADMINPEN:
• Painless relative to a standard syringe.
• Simple and intuitive to use.
• Reliable Uniform Insertion into flexible skin via convex microneedle array
• No Reformulation Required. Uses existing formulations.
• 16x Amplified Immunity via delivery over 1 cm2 skin area directly to immune cells
• Biocompatible medical-grade materials.
• Compatible with a standard syringe.
• Eliminates sharps hazards.
• Low-cost, high-speed manufacturing.
• 510(k) regulatory approval route.
• 4 US and EU Patents Granted
• 60+ scientific publications.
• Strong Traction. Generated $500k+ in revenue from 500+ customers worldwide.

Next Steps:
• Scale up & validate GMP manufacturing
• Perform GLP-1 preclinical & clinical studies
• Obtain CE Mark in EU and 510(k) in US
• Enter a strategic licensing agreement

The Company welcomes inquiries about its products and programs from investors and potential strategic partners. Please use the following button to access the form for contacting the management team:
https://www.adminmed.com/contact/